SCHEMBL2465670

SCHEMBL2465670

CN1CCN(c2nc3ccc(C(F)(F)F)c(F)c3c3ncnn23)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH4 Q9H3N8 2/20 0.43
HRH3 Q9Y5N1 1/20 0.43
CYP1A2 P05177 5/20 0.40
TSHR P16473 5/20 0.40
CYP2C19 P33261 4/20 0.40
CYP3A4 P08684 4/20 0.40
CYP2D6 P10635 4/20 0.40
ALDH1A1 P00352 3/20 0.40
KDM4E B2RXH2 1/20 0.40
HSD17B10 Q99714 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
MAPK1 P28482 5/20 0.39
USP2 O75604 4/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
HIF1A Q16665 1/20 0.39
HTR3E A5X5Y0 1/20 0.37
HTR3B O95264 1/20 0.37
HTR3A P46098 1/20 0.37
HTR3D Q70Z44 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2465334 0.87 CYP1A2 (0.40) CYP1A2CYP2C19ALDH1A1KDM4EHTR3A
SCHEMBL2461806 0.86 HRH4 (0.45) HRH4HRH3CYP1A2TSHRCYP2C19
SCHEMBL2465329 0.85 MTOR (0.34) KDM4EKMT2ACNR2NPSR1GAA
SCHEMBL12225096 0.85 HRH4 (0.46) HRH4HRH3TSHRALDH1A1KDM4E
SCHEMBL2464857 0.84 HRH4 (0.50) HRH4HRH3TSHRALDH1A1MAPK1
SCHEMBL462645 0.83 HRH4 (0.42) HRH4CYP1A2TSHRCYP2C19CYP3A4
Hydrochloric Acid SCHEMBL439832 0.82 HRH4 (0.41) HRH4CYP1A2TSHRCYP2C19CYP3A4
SCHEMBL2464899 0.82 HRH4 (0.46) HRH4
SCHEMBL2463455 0.78 MBOAT4 (0.34) ALDH1A1KDM4E
SCHEMBL12224901 0.78 HRH4 (0.51) HRH4HRH3CYP1A2TSHRCYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110257137-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE KALYPSYS, INC. (US) 2011-10-20 US disclosed
US-20110257137-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE KALYPSYS, INC. (US) 2011-10-20 US disclosed
US-20110257137-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE KALYPSYS, INC. (US) 2011-10-20 US disclosed
WO-2011112731-A2 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE KALYPSYS, INC. (US) 2011-09-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110257137-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE HRH4, HRH3, HRH2 HRH4 1/4885HRH3 2/4885CYP1A2 2609/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.